RÉSUMÉ
Edwardsiella ictaluri is a Gram-negative, facultative intracellular bacterium that causes enteric septicemia in catfish (ESC). The RNA chaperone Hfq (host factor for phage Qß replication) facilitates gene regulation via small RNAs (sRNAs) in various pathogenic bacteria. Despite its significance in other bacterial species, the role of hfq in E. ictaluri remains unexplored. This study aimed to elucidate the role of hfq in E. ictaluri by creating an hfq mutant (EiΔhfq) through in-frame gene deletion and characterization. Our findings revealed that the Hfq protein is highly conserved within the genus Edwardsiella. The deletion of hfq resulted in a significantly reduced growth rate during the late exponential phase. Additionally, EiΔhfq displayed a diminished capacity for biofilm formation and exhibited increased motility. Under acidic and oxidative stress conditions, EiΔhfq demonstrated impaired growth, and we observed elevated hfq expression when subjected to in vitro and in vivo stress conditions. EiΔhfq exhibited reduced survival within catfish peritoneal macrophages, although it had no discernible effect on the adherence and invasion of epithelial cells. The infection model revealed that hfq is needed for bacterial persistence in catfish, and its absence caused significant virulence attenuation in catfish. Finally, the EiΔhfq vaccination completely protected catfish against subsequent EiWT infection. In summary, these results underscore the pivotal role of hfq in E. ictaluri, affecting its growth, motility, biofilm formation, stress response, and virulence in macrophages and within catfish host.
Sujet(s)
Biofilms , Poissons-chats , Edwardsiella ictaluri , Infections à Enterobacteriaceae , Protéine IHF-1 , Edwardsiella ictaluri/génétique , Edwardsiella ictaluri/pathogénicité , Animaux , Protéine IHF-1/métabolisme , Protéine IHF-1/génétique , Biofilms/croissance et développement , Infections à Enterobacteriaceae/microbiologie , Poissons-chats/microbiologie , Maladies des poissons/microbiologie , Virulence , Macrophages/microbiologie , Délétion de gène , Régulation de l'expression des gènes bactériens , Stress oxydatif , Cellules épithéliales/microbiologie , Adhérence bactérienne/génétiqueRÉSUMÉ
BACKGROUND: Infections caused by multi-drug resistant Gram-negative pathogens are associated with worse clinical outcomes in critically ill patients. We evaluated hospital outcomes based on adequacy of overall and newer antibacterial therapy for Enterobacterales (ENT) and Pseudomonas aeruginosa (PsA) in US patients. METHODS: Hospitalized adults ≥ 18 years old with facility-reported antibiotic susceptibility from 2018-2022 across 161 facilities in the BD Insights Research Database were identified as ENT- or PsA-positive. Generalized linear mixed models were used to evaluate the impact of inadequate empiric therapy (IET) and time to initiate newer antibacterials (ceftazidime-avibactam; ceftolozane-tazobactam; cefiderocol; meropenem-vaborbactam; eravacycline; and imipenem-cilcastatin-relebactam) on hospital mortality and post-culture length of stay (LOS). RESULTS: Among 229,320 ENT and 36,027 PsA susceptibility results, 1.7% and 16.8% were carbapenem non-susceptible (carb-NS), respectively. Median time to first susceptibility result was longer for carb-NS vs. carb susceptible in ENT (64 h vs. 48 h) and PsA (67 h vs. 60 h). For ENT, IET was associated with significantly higher mortality (odds ratio [OR],1.29 [95% CI, 1.16-1.43, P < 0.0001]) and longer hospital LOS (14.8 vs. 13.3, P < 0.0001). Delayed start to newer antibacterial therapy was associated with significantly greater hospital mortality for ENT (P = 0.0182) and PsA (P = 0.0249) and significantly longer post-culture LOS for ENT (P < 0.0001) and PsA (P < 0.0001). CONCLUSIONS: Overall, IET and delayed use of newer antibacterials are associated with significantly worse hospital outcomes. More rapid identification of high-risk patients can facilitate adequate therapy and timely use of newer antibacterials developed for resistant Gram-negative pathogens.
Sujet(s)
Antibactériens , Infections à Pseudomonas , Pseudomonas aeruginosa , Humains , Antibactériens/usage thérapeutique , Femelle , Mâle , Pseudomonas aeruginosa/effets des médicaments et des substances chimiques , Adulte d'âge moyen , Sujet âgé , Infections à Pseudomonas/traitement médicamenteux , Infections à Pseudomonas/microbiologie , Infections à Pseudomonas/mortalité , Adulte , Infections à Enterobacteriaceae/traitement médicamenteux , Infections à Enterobacteriaceae/microbiologie , Infections à Enterobacteriaceae/mortalité , Tests de sensibilité microbienne , Hospitalisation , Durée du séjour , Mortalité hospitalière , Enterobacteriaceae/effets des médicaments et des substances chimiques , Multirésistance bactérienne aux médicaments , Résultat thérapeutique , Sujet âgé de 80 ans ou plus , États-UnisRÉSUMÉ
The extended-spectrum ß-lactamases (ESßLs) are bacterial enzymes capable of hydrolyzing penicillins, cephalosporins, and aztreonam. The prevalence of ESßL is increasing among clinically significant microorganisms worldwide, drastically reducing the therapeutic management of infectious diseases. The study aimed to determine the drug susceptibility of ESßL-positive clinical isolates acquired from patients hospitalized in Lodz, central Poland, and analyze the prevalence of specific genes, determining acquired resistance in these bacteria. The samples of ESßL-positive clinical isolates were gathered in 2022 from medical microbiological laboratories in the city of Lodz, central Poland. The strains were subjected to biochemical identification and antimicrobial susceptibility testing following EUCAST guidelines. The presence of studied genes (blaCTX-M, blaSHV, blaTEM, blaPER, blaVEB) was confirmed by PCR. Over 50% of studied isolates were resistant to gentamicin, cefepime, ceftazidime and ciprofloxacin. The most common ESßL gene was blaCTX-M. In most isolates, the resistance genes occurred simultaneously. The blaPER was not detected in any of the tested strains. ESßL-producing strains are largely susceptible to the currently available antibiotics. The observation of the coexistence of different genes in most clinical isolates is alarming.
Sujet(s)
Antibactériens , Infections à Enterobacteriaceae , Enterobacteriaceae , Tests de sensibilité microbienne , bêta-Lactamases , Humains , bêta-Lactamases/génétique , bêta-Lactamases/métabolisme , Pologne/épidémiologie , Antibactériens/pharmacologie , Infections à Enterobacteriaceae/microbiologie , Infections à Enterobacteriaceae/épidémiologie , Infections à Enterobacteriaceae/traitement médicamenteux , Enterobacteriaceae/génétique , Enterobacteriaceae/effets des médicaments et des substances chimiques , Enterobacteriaceae/isolement et purification , Enterobacteriaceae/enzymologie , Épidémiologie moléculaire , Mâle , Femelle , Adulte , Adulte d'âge moyen , Ciprofloxacine/pharmacologieRÉSUMÉ
AIMS: Adequately and accurately identifying carbapenemase-producing Enterobacterales (CPE) is vital for selecting appropriate antimicrobial therapy and implementing effective infection control measures. This study aims to optimize the phenotypic detection method of carbapenemase for routine diagnostics in clinical microbiology laboratories. METHODS AND RESULTS: Carbapenemase genes in 2665 non-duplicate CRE clinical strains collected from various regions of China were confirmed through whole-genome sequencing (WGS). The carbapenemase inhibition test (CIT) was conducted and interpreted using different methods and breakpoints, then compared with the NG-Test CARBA 5 for carbapenemase detection. The diagnostic performance of the CIT method was optimal when the carbapenemase types were determined by comparing the inhibition zone diameters of the imipenem disc with 3-aminophenylboronic acid (APB) plus ethylenediaminetetraacetic acid (EDTA) to those of the imipenem disc with either APB or EDTA alone, with a breakpoint of 4 mm. The overall sensitivities of the current CIT, the modified CIT, and NG-Test CARBA 5 were 91.4%, 94.9%, and 99.9%, respectively. For detecting isolates co-producing Klebsiella pneumoniae carbapenemase (KPC) and metallo-ß-lactamases (MBLs), the modified CIT method had higher sensitivity than the current method (70.0% vs. 53.3%), though this difference was not statistically significant (P = 0.063). The NG-Test CARBA 5 showed excellent performance for multi-carbapenemases diagnosis, with sensitivity and specificity of 97.1% and 100%, respectively. CONCLUSIONS: Optimizing and standardizing the CIT method for clinical use is necessary. It has certain advantages in diagnosing multi-carbapenemase and rare carbapenemase production. However, for identifying common carbapenemase types, the NG-Test CARBA 5 demonstrated superior performance.
Sujet(s)
Protéines bactériennes , bêta-Lactamases , bêta-Lactamases/métabolisme , bêta-Lactamases/analyse , Protéines bactériennes/métabolisme , Humains , Chine , Imipénem/pharmacologie , Tests de sensibilité microbienne , Antibactériens/pharmacologie , Enterobacteriaceae résistantes aux carbapénèmes/isolement et purification , Enterobacteriaceae résistantes aux carbapénèmes/enzymologie , Enterobacteriaceae résistantes aux carbapénèmes/effets des médicaments et des substances chimiques , Sensibilité et spécificité , Séquençage du génome entier , Enterobacteriaceae/effets des médicaments et des substances chimiques , Enterobacteriaceae/enzymologie , Enterobacteriaceae/isolement et purification , Infections à Enterobacteriaceae/microbiologieRÉSUMÉ
BACKGROUND: Infections resulting from multidrug-resistant Enterobacterales (MDR-E) pose a growing global threat, presenting challenges in treatment and contributing significantly to morbidity and mortality rates. The main objective of this study was to characterize phenotypically and genetically extended-spectrum ß-lactamase- and carbapenemase- producing Enterobacterales (ESBLE and CPE respectively) isolated from clinical samples in the West Bank, Palestine. METHODS: A cross sectional study was conducted in October 2023 on clinical bacterial isolates collected from five governmental hospitals in the West Bank, Palestine. The isolates obtained from the microbiology laboratories of the participating hospitals, underwent identification and antibiotic susceptibility testing (AST) using the VITEK® 2 Compact system. ESBL production was determined by the Vitek2 Compact system. A modified carbapenem inactivation method (mCIM) was employed to identify carbapenemase-producing Enterobacterales (CPE). Resistance genes were detected by real-time PCR. RESULTS: Out of the total 1380 collected isolates, we randomly selected 600 isolates for analysis. Our analysis indicated that 287 (47.83%) were extended-spectrum beta-lactamase producers (ESBLE), and 102 (17%) as carbapenem-resistant Enterobacterales (CRE) isolates. A total of 424 isolates (70.67%) were identified as multidrug-resistant Enterobacterales (MDRE). The most prevalent ESBL species were K. pneumoniae (n = 124; 43.2%), E. coli (n = 119; 41.5%) and E. cloacae (n = 31; 10.8%). Among the CRE isolates, 85 (83.33%) were carbapenemase-producing Enterobacterales (CPE). The most frequent CRE species were K. pneumoniae (n = 63; 61.7%), E. coli (n = 25; 24.5%) and E. cloacae (n = 13; 12.8%). Additionally, 47 (7.83%) isolates exhibited resistance to colistin (CT), with 38 (37.62%) being CT-resistant CRE and 9 (3.14%) being CT-resistant ESBLE while sensitive to carbapenems. We noticed that 11 isolates (6 Klebsiella pneumoniae and 5 Enterobacter cloacae complex) demonstrated sensitivity to carbapenems by phenotype but carried silent CPE genes (1 blaOXA48, and 6 blaNDM, 4 blaOXA48, blaNDM). ESBL-producing Enterobacterales strains exhibited varied resistance patterns across different antibiotic classes. E. coli isolates showed notable 48% resistance to trimethoprim/sulfamethoxazole. K. pneumoniae isolates displayed a significant resistance to trimethoprim/sulfamethoxazole, nitrofurantoin, and fosfomycin (54%, 90%, and 70% respectively). E. cloacae isolates showed complete resistance to nitrofurantoin and fosfomycin. P. mirabilis isolates exhibited high resistance against fluoroquinolones (83%), and complete resistance to trimethoprim/sulfamethoxazole, nitrofurantoin and fosfomycin. CONCLUSION: This study showed the high burden of the ESBLE and CRE among the samples collected from the participating hospitals. The most common species were K. pneumoniae and E. coli. There was a high prevalence of blaCTXm. Adopting both conventional and molecular techniques is essential for better surveillance of the emergence and spread of antimicrobial-resistant Enterobacterales infections in Palestine.
Sujet(s)
Antibactériens , Protéines bactériennes , Multirésistance bactérienne aux médicaments , Infections à Enterobacteriaceae , Enterobacteriaceae , Tests de sensibilité microbienne , bêta-Lactamases , Humains , bêta-Lactamases/génétique , Études transversales , Infections à Enterobacteriaceae/microbiologie , Infections à Enterobacteriaceae/épidémiologie , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme , Multirésistance bactérienne aux médicaments/génétique , Antibactériens/pharmacologie , Moyen Orient/épidémiologie , Femelle , Adulte , Enterobacteriaceae/génétique , Enterobacteriaceae/effets des médicaments et des substances chimiques , Enterobacteriaceae/isolement et purification , Enterobacteriaceae/enzymologie , Mâle , Adulte d'âge moyen , Phénotype , Enterobacteriaceae résistantes aux carbapénèmes/génétique , Enterobacteriaceae résistantes aux carbapénèmes/isolement et purification , Enterobacteriaceae résistantes aux carbapénèmes/effets des médicaments et des substances chimiques , Jeune adulte , Adolescent , Sujet âgé , Enfant , Carbapénèmes/pharmacologie , Enfant d'âge préscolaireRÉSUMÉ
Background: Aminoglycoside-modifying enzymes (AMEs) play an essential role in bacterial resistance to aminoglycoside antimicrobials. With the development of sequencing techniques, more bacterial genomes have been sequenced, which has aided in the discovery of an increasing number of novel resistance mechanisms. Methods: The bacterial species was identified by 16S rRNA gene homology and average nucleotide identity (ANI) analyses. The minimum inhibitory concentration (MIC) of each antimicrobial was determined by the agar dilution method. The protein was expressed with the pCold I vector in E. coli BL21, and enzyme kinetic parameters were examined. The whole-genome sequence of the bacterium was obtained via the Illumina and PacBio sequencing platforms. Reconstruction of the phylogenetic tree, identification of conserved functional residues, and gene context analysis were performed using the corresponding bioinformatic techniques. Results: A novel aminoglycoside resistance gene, designated aph(3')-Ie, which confers resistance to ribostamycin, kanamycin, sisomicin and paromomycin, was identified in the chromosome of the animal bacterium Citrobacter gillenii DW61, which exhibited a multidrug resistance phenotype. APH(3')-Ie showed the highest amino acid identity of 74.90% with the functionally characterized enzyme APH(3')-Ia. Enzyme kinetics analysis demonstrated that it had phosphorylation activity toward four aminoglycoside substrates, exhibiting the highest affinity (K m, 4.22 ± 0.88 µM) and the highest catalytic efficiency [k cat/K m, (32.27 ± 8.14) × 104] for ribomycin. Similar to the other APH(3') proteins, APH(3')-Ie contained all the conserved functional sites of the APH family. The aph(3')-Ie homologous genes were present in C. gillenii isolates from different sources, including some of clinical significance. Conclusion: In this work, a novel chromosomal aminoglycoside resistance gene, designated aph(3')-Ie, conferring resistance to aminoglycoside antimicrobials, was identified in a rabbit isolate C. gillenii DW61. The elucidation of the novel resistance mechanism will aid in the effective treatment of infections caused by pathogens carrying such resistance genes.
Sujet(s)
Aminosides , Antibactériens , Citrobacter , Tests de sensibilité microbienne , Phylogenèse , ARN ribosomique 16S , Animaux , Antibactériens/pharmacologie , Antibactériens/métabolisme , Citrobacter/enzymologie , Citrobacter/génétique , Citrobacter/métabolisme , Citrobacter/classification , Aminosides/pharmacologie , Aminosides/métabolisme , ARN ribosomique 16S/génétique , Lapins , Multirésistance bactérienne aux médicaments/génétique , Génome bactérien , Séquençage du génome entier , Sisomicine/pharmacologie , Sisomicine/analogues et dérivés , Sisomicine/métabolisme , Kanamycin kinase/génétique , Kanamycin kinase/métabolisme , Ribostamycine/métabolisme , Résistance bactérienne aux médicaments/génétique , Kanamycine/pharmacologie , Escherichia coli/génétique , Escherichia coli/métabolisme , Infections à Enterobacteriaceae/microbiologieRÉSUMÉ
BACKGROUND: Hospitals in any given region can be considered as part of a network, where facilities are connected to one another - and hospital pathogens potentially spread - through the movement of patients between them. We sought to describe the hospital admission patterns of patients known to be colonised with carbapenemase-producing Enterobacterales (CPE), and compare them with CPE-negative patient cohorts, matched on comorbidity information. METHODS: We performed a linkage study in Victoria, Australia, including datasets with notifiable diseases (CPE notifications) and hospital admissions (admission dates and diagnostic codes) for the period 2011 to 2020. Where the CPE notification date occurred during a hospital admission for the same patient, we identified this as the 'index admission'. We determined the number of distinct health services each patient was admitted to, and time to first admission to a different health service. We compared CPE-positive patients with four cohorts of CPE-negative patients, sampled based on different matching criteria. RESULTS: Of 528 unique patients who had CPE detected during a hospital admission, 222 (42%) were subsequently admitted to a different health service during the study period. Among these patients, CPE diagnosis tended to occur during admission to a metropolitan public hospital (86%, 190/222), whereas there was a greater number of metropolitan private (23%, 52/222) and rural public (18%, 39/222) hospitals for the subsequent admission. Median time to next admission was 4 days (IQR, 0-75 days). Admission patterns for CPE-positive patients was similar to the cohort of CPE-negative patients matched on index admission, time period, and age-adjusted Charlson comorbidity index. CONCLUSIONS: Movement of CPE-positive patients between health services is not a rare event. While the most common movement is from one public metropolitan health service to another, there is also a trend for movement from metropolitan public hospitals into private and rural hospitals. After accounting for clinical comorbidities, CPE colonisation status does not appear to impact on hospital admission frequency or timing. These findings support the potential utility of a centralised notification and outbreak management system for CPE positive patients.
Sujet(s)
Protéines bactériennes , Infections à Enterobacteriaceae , bêta-Lactamases , Humains , Infections à Enterobacteriaceae/épidémiologie , Infections à Enterobacteriaceae/microbiologie , Mâle , Femelle , Adulte d'âge moyen , Victoria/épidémiologie , Sujet âgé , bêta-Lactamases/métabolisme , Protéines bactériennes/métabolisme , Hospitalisation , Adulte , Enterobacteriaceae résistantes aux carbapénèmes , Admission du patient , Enterobacteriaceae , Infection croisée/microbiologie , Infection croisée/épidémiologie , Sujet âgé de 80 ans ou plus , Jeune adulte , État de porteur sain/épidémiologie , État de porteur sain/microbiologieRÉSUMÉ
Carbapenem-resistant Enterobacteriaceae (CRE) have diminished treatment options causing serious morbidities and mortalities. This systematic review and meta-analysis assessed the prevalence and associated factors of Enterobacteriaceae infections in clinical, livestock and environmental settings globally. The population intervention comparison and outcome strategy was used to enroll studies using the preferred reporting system for systematic review and meta-analysis to include only cross-sectional studies. Search engines used to retrieve articles included journal author name estimator, PubMed, Google Scholar and African Journals Online (AJOL). The Newcastle-Ottawa scale was used to assess the quality of studies. Sixteen articles from 2013 to 2023 in Africa, Asia, Europe and South America were studied. The pooled prevalence of CRE was 43.06% (95% CI 21.57-66.03). Klebsiella pneumoniae (49.40%), Escherichia coli (26.42%), and Enterobacter cloacae (14.24%) were predominant. Klebsiella pneumoniae had the highest resistance with the blaKPC-2 in addition to blaNDM, blaOXA-48, blaIMP and blaVIM. The blaKPC-2 genes occurrence was associated with environmental (P-value < 0.0001) and South American studies (P-value < 0.0001), but there was no difference in the trends over time (P-value = 0.745). This study highlights the high rates of CRE infections, particularly within blaKPC production. Monitoring and surveillance programs, research and infection control measures should be strengthened. Additionally, further studies are needed to explore the mechanisms driving the predominance of specific bacterial species and the distribution of resistance genes within this bacterial family.
Sujet(s)
Enterobacteriaceae résistantes aux carbapénèmes , Infections à Enterobacteriaceae , Bétail , Enterobacteriaceae résistantes aux carbapénèmes/génétique , Enterobacteriaceae résistantes aux carbapénèmes/isolement et purification , Animaux , Bétail/microbiologie , Humains , Infections à Enterobacteriaceae/épidémiologie , Infections à Enterobacteriaceae/microbiologie , Infections à Enterobacteriaceae/traitement médicamenteux , Prévalence , Antibactériens/pharmacologie , Klebsiella pneumoniae/effets des médicaments et des substances chimiques , Klebsiella pneumoniae/génétique , Carbapénèmes/pharmacologie , Carbapénèmes/usage thérapeutiqueRÉSUMÉ
Background/purposes: The continuously increasing carbapenem resistance within Enterobacterales and Pseudomonas poses a threat to public health, nevertheless, the molecular characteristics of which in southern China still remain limited. And carbapenemase identification is a key factor in effective early therapy of carbapenem-resistant bacteria infections. We aimed to determine the molecular characteristics of these pathogens and compare commercial combined disc tests (CDTs) with the modified carbapenem inactivation method (mCIM) and EDTA-CIM (eCIM) in detecting and distinguishing carbapenemases using whole genome sequencing (WGS). Methods: A total of 78 Enterobacterales, 30 Pseudomonas were obtained from two tertiary hospitals in southern China. Susceptibility tests were conducted using an automated VITEK2 compact system with confirmation via the Kirby-Bauer method. The WGS was conducted on all clinical isolates and the molecular characteristics were analyzed by screening the whole genome sequences. CDTs with or without cloxacillin, mCIM, and eCIM, were performed and compared by taking WGS results as the benchmark. Results: A total of 103 carbapenem non-susceptible and 5 carbapenem susceptible bacteria were determined, with Klebsiella pneumoniae (42.7%), Pseudomonas aeruginosa (23.3%) and Escherichia coli (18.4%) being most prevalent. Carbapenemase genes were detected in 58 (56.3%) of the 103 carbapenem-non-susceptible clinical isolates, including 46 NDM, 6 KPC, 3 IMP, 1 IPM+VIM,1NDM+KPC, and 1 OXA-181. Carbapenemase-producing isolates were detected more frequently in Enterobacterales (76.3%). Among K. pneumoniae, the major sequence types were st307 and st11, while among E. coli and P. aeruginosa, the most prevalent ones were st410 and st242 respectively. For carbapenemase detection in Enterobacterales, the mCIM method achieved 100.00% (95% CI, 92.13-100.00%) sensitivity and 94.44% (70.63-99.71%) specificity (kappa, 0.96); for Pseudomonas, detection sensitivity was 100% (5.46-100.00%), and 100% (84.50-100.00%) specificity (kappa, 0.65). Commercial CDT carbapenemase detection sensitivity for Enterobacterales was 96.49% (86.84-99.39%), and 95.24% (74.13-99.75%) specificity (kappa, 0.90); for Pseudomonas, carbapenemase detection sensitivity was 100.00% (5.46-100.00%) and 37.93% (21.30-57.64%) specificity (kappa, 0.04). When cloxacillin testing was added, CDT specificity reached 84.61% (64.27-94.95%). Conclusion: The molecular epidemiology of carbapenem-non-susceptible isolates from pediatric patients in Southern China exhibited distinctive characteristics. Both the mCIM-eCIM combination and CDT methods effectively detected and differentiated carbapenemases among Enterobacterales isolates, and the former performed better than CDT among Pseudomonas.
Sujet(s)
Antibactériens , Protéines bactériennes , Tests de sensibilité microbienne , Pseudomonas , Séquençage du génome entier , bêta-Lactamases , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme , Séquençage du génome entier/méthodes , bêta-Lactamases/génétique , Humains , Pseudomonas/génétique , Pseudomonas/effets des médicaments et des substances chimiques , Pseudomonas/enzymologie , Pseudomonas/isolement et purification , Chine , Antibactériens/pharmacologie , Enterobacteriaceae/génétique , Enterobacteriaceae/effets des médicaments et des substances chimiques , Enterobacteriaceae/enzymologie , Enterobacteriaceae/isolement et purification , Carbapénèmes/pharmacologie , Génome bactérien , Infections à Enterobacteriaceae/microbiologie , Infections à Pseudomonas/microbiologie , Phénotype , Pseudomonas aeruginosa/génétique , Pseudomonas aeruginosa/effets des médicaments et des substances chimiques , Pseudomonas aeruginosa/enzymologie , Pseudomonas aeruginosa/isolement et purificationRÉSUMÉ
BACKGROUND: Enterobacter cloacae complex (ECC) including different species are isolated from different human clinical samples. ECC is armed by many different virulence genes (VGs) and they were also classified among ESKAPE group by WHO recently. The present study was designed to find probable association between VGs and antibiotic susceptibility in different ECC species. METHODS: Forty-five Enterobacter isolates that were harvested from different clinical samples were classified in four different species. Seven VGs were screened by PCR technique and antibiotic susceptibility assessment was performed by disk-diffusion assay. RESULT: Four Enterobacter species; Enterobacter cloacae (33.3%), Enterobacter hormaechei (55.6%), Enterobacter kobei (6.7%) and Enterobacter roggenkampii (4.4%) were detected. Minimum antibiotic resistance was against carbapenem agents and amikacin even in MDR isolates. 33.3% and 13.3% of isolates were MDR and XDR respectively. The rpoS (97.8%) and csgD (11.1%) showed maximum and minimum frequency respectively. Blood sample isolated were highly virulent but less resistant in comparison to the other sample isolates. The csgA, csgD and iutA genes were associated with cefepime sensitivity. CONCLUSION: The fepA showed a predictory role for differentiating of E. hormaechei from other species. More evolved iron acquisition system in E. hormaechei was hypothesized. The fepA gene introduced as a suitable target for designing novel anti-virulence/antibiotic agents against E. hormaechei. Complementary studies on other VGs and ARGs and with bigger study population is recommended.
Sujet(s)
Antibactériens , Enterobacter cloacae , Infections à Enterobacteriaceae , Tests de sensibilité microbienne , Facteurs de virulence , Humains , Antibactériens/pharmacologie , Enterobacter cloacae/génétique , Enterobacter cloacae/effets des médicaments et des substances chimiques , Enterobacter cloacae/isolement et purification , Enterobacter cloacae/pathogénicité , Infections à Enterobacteriaceae/microbiologie , Facteurs de virulence/génétique , Virulence/génétique , Protéines bactériennes/génétique , Multirésistance bactérienne aux médicaments/génétique , Enterobacter/génétique , Enterobacter/effets des médicaments et des substances chimiques , Enterobacter/isolement et purification , Mâle , FemelleRÉSUMÉ
Cronobacter species are opportunistic pathogens that are capable of causing morbidity and mortality, particularly in infants. Although the transmission dynamics involved in Cronobacter infections remain largely unknown, contaminated powdered infant formula (PIF) has been linked to 30% of Cronobacter sakazakii cases involving invasive illness in infants. As several lines of evidence have implicated the domestic environment in PIF contamination, we undertook a microbiological survey of homes (N = 263) across the US. Cronobacter spp. and C. sakazakii were isolated from 36.1% and 24.7% of US homes, respectively, with higher recovery rates observed for floor and kitchen surfaces. Multi-locus sequence typing indicated that the dominant strain was C. sakazakii ST4, the sequence type most commonly associated with neonatal meningitis. For comparison purposes, retail foods (N = 4,009) were also surveyed, with the highest contamination frequencies (10.1%-26.3%) seen for nut products, seeds, and grains/baked goods/flours. The sequence type profile of isolates recovered from homes mirrored that of isolates recovered from retail foods, with increased representation of ST1, ST4, ST13, ST17, and ST40. Analysis of 386 whole genomic sequences revealed significant diversity. Redundancies were only observed for isolates recovered from within the same domicile, and there were no identical matches with sequences archived at the NCBI pathogen database. Genes coding for putative virulence and antibiotic resistance factors did not segregate with clinically significant sequence types. Collectively, these findings support the possibility that contamination events occurring within the home should not be overlooked as a contributor to community-onset Cronobacter infections. IMPORTANCE: Cronobacter sakazakii is an opportunistic pathogen that can cause significant morbidity and mortality in neonates. Its transmission dynamics are poorly understood, though powered infant formula (PIF) is thought to be the major transmission vehicle. How the PIF becomes contaminated remains unknown. Our survey shows that roughly 1/4 of US homes are contaminated with Cronobacter sakazakii, particularly in the kitchen setting. Our analyses suggest that the domestic environment may contribute to contamination of PIF and provides insights into mitigating the risk of transmission.
Sujet(s)
Cronobacter sakazakii , Microbiologie alimentaire , Préparation pour nourrissons , Cronobacter sakazakii/génétique , Cronobacter sakazakii/isolement et purification , Cronobacter sakazakii/classification , États-Unis , Humains , Préparation pour nourrissons/microbiologie , Typage par séquençage multilocus , Génome bactérien , Nourrisson , Infections à Enterobacteriaceae/microbiologie , Infections à Enterobacteriaceae/transmission , Caractéristiques familiales , GénomiqueRÉSUMÉ
Delayed time to antimicrobial susceptibility results can impact patients' outcomes. Our study evaluated the impact of susceptibility turnaround time (TAT) and inadequate empiric antibacterial therapy (IET) in patients with bloodstream infections (BSI) caused by Enterobacterales (ENT) species on in-hospital mortality and length of stay (LOS). This retrospective, multicenter investigation which included 29,570 blood ENT-positive admissions across 161 US healthcare facilities evaluated the association between antimicrobial susceptibility testing (AST) TAT, carbapenem susceptibility, and empiric therapy on post-BSI in-hospital mortality and LOS following an ENT BSI event in adult patients. After adjusting for outcomes covariates, post-BSI in-hospital mortality was significantly higher for patients in the IET vs adequate empiric therapy (AET) group [odds ratio (OR): 1.61 (95% CI: 1.32, 1.98); P < 0.0001], and when AST TAT was >63 h [OR:1.48 (95% CI: 1.16, 1.90); P = 0.0017]. Patients with carbapenem non-susceptible (carb-NS) ENT BSI had significantly higher LOS (16.6 days, 95% CI: 15.6, 17.8) compared to carbapenem susceptible (carb-S, 12.2 days, 95% CI: 11.8, 12.6), (P < 0.0001). Extended AST TAT was significantly associated with longer LOS for TAT of 57-65 h and >65 h (P = 0.005 and P< 0.0001, respectively) compared to TAT ≤42 h (reference). Inadequate empiric therapy (IET), carb-NS, and delayed AST TAT are significantly associated with adverse hospital outcomes in ENT BSI. Workflows that accelerate AST TAT for ENT BSIs and facilitate timely and adequate therapy may reduce post-BSI in-hospital mortality rate and LOS.IMPORTANCEFor patients diagnosed with bloodstream infections (BSI) caused by Enterobacterales (ENT), delayed time to antimicrobial susceptibility (AST) results can significantly impact in-hospital mortality and hospital length of stay. However, this relationship between time elapsed from blood culture collection to AST results has only been assessed, to date, in a limited number of publications. Our study focuses on this important gap using retrospective data from 29,570 blood ENT-positive admissions across 161 healthcare facilities in the US as we believe that a thorough understanding of the dynamic between AST turnaround time, adequacy of empiric therapy, post-BSI event mortality, and hospital length of stay will help guide effective clinical management and optimize outcomes of patients with ENT infections.
Sujet(s)
Antibactériens , Bactériémie , Hémoculture , Infections à Enterobacteriaceae , Mortalité hospitalière , Durée du séjour , Humains , Durée du séjour/statistiques et données numériques , Études rétrospectives , Mâle , Femelle , Infections à Enterobacteriaceae/mortalité , Infections à Enterobacteriaceae/traitement médicamenteux , Infections à Enterobacteriaceae/microbiologie , Antibactériens/usage thérapeutique , Antibactériens/pharmacologie , Adulte d'âge moyen , Bactériémie/mortalité , Bactériémie/traitement médicamenteux , Bactériémie/microbiologie , Sujet âgé , Tests de sensibilité microbienne , Carbapénèmes/usage thérapeutique , Carbapénèmes/pharmacologie , Enterobacteriaceae/effets des médicaments et des substances chimiques , Adulte , Sujet âgé de 80 ans ou plusRÉSUMÉ
OBJECTIVES: We evaluated the effect of fecal microbiota transplantation (FMT) on the clearance of carbapenemase-producing Enterobacterales (CPE) carriage. METHODS: We performed a prospective, multi-center study, conducted among patients who received a single dose of FMT from one of four healthy donors. The primary endpoint was complete clearance of CPE carriage two weeks after FMT with a secondary endpoint at three months. Shotgun metagenomic sequencing was performed to assess gut microbiota composition of donors and recipients before and after FMT. RESULTS: Twenty CPE-colonized patients were included in the study, where post-FMT 20% (n = 4/20) of patients met the primary endpoint and 40% (n = 8/20) of patients met the secondary endpoint. Kaplan-Meier curves between patients with FMT intervention and the control group (n = 82) revealed a similar rate of decolonization between groups. Microbiota composition analyses revealed that response to FMT was not donor-dependent. Responders had a significantly lower relative abundance of CPE species pre-FMT than non-responders, and 14 days post-FMT responders had significantly higher bacterial species richness and alpha diversity compared to non-responders (p < 0.05). Responder fecal samples were also enriched in specific species, with significantly higher relative abundances of Faecalibacterium prausnitzii, Parabacteroides distasonis, Collinsella aerofaciens, Alistipes finegoldii and Blautia_A sp900066335 (q<0.01) compared to non-responders. CONCLUSION: FMT administration using the proposed regimen did not achieve statistical significance for complete CPE decolonization but was correlated with the relative abundance of specific bacterial taxa, including CPE species.
Sujet(s)
Transplantation de microbiote fécal , Fèces , Microbiome gastro-intestinal , Humains , Mâle , Femelle , Adulte d'âge moyen , Études prospectives , Adulte , Fèces/microbiologie , Sujet âgé , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme , Infections à Enterobacteriaceae/thérapie , Infections à Enterobacteriaceae/microbiologie , bêta-Lactamases/génétique , État de porteur sain/microbiologie , État de porteur sain/thérapie , Enterobacteriaceae résistantes aux carbapénèmes/génétique , Enterobacteriaceae résistantes aux carbapénèmes/isolement et purification , BiodiversitéRÉSUMÉ
Antimicrobial resistance and biofilm formation by microbial pathogens pose a significant challenge to poultry production systems due to the persistent risk of dissemination and compromise of bird health and productivity. In this context, the study aimed to investigate the occurrence of different multiresistance phenotypes and the biofilm-forming ability of Enterobacteriaceae isolated from broiler chicken excreta in poultry production units in Ceará, Brazil. Samples were collected from three distinct broiler breeding facilities and subjected to isolation, identification, antibiotic susceptibility testing, phenotypic screening for ß-lactamases enzymes, and biofilm formation evaluation. Seventy-one strains were identified, being Escherichia coli (37 %) and Proteus mirabilis (32 %), followed by Klebsiella pneumoniae (11 %), Providencia stuartii (9 %), Klebsiella aerogenes (6 %), Alcaligenes faecalis (4 %), and Salmonella sp. (1 %). A significant proportion (87 %) of multiresistant strains were detected. For the phenotypic evaluation of ß-lactamases production, strains with resistance to second and third-generation cephalosporins and carbapenems were tested. About 4 of 6 and 10 of 26 were positive for inducible chromosomal AmpC ß-lactamase and extended-spectrum ß-lactamase (ESBL), respectively. Regarding biofilm formation, it was observed that all MDR strains were capable of forming biofilm. In this sense the potential of these MDR bacteria to develop biofilms becomes a significant concern, representing a real threat to both human and animal health, as biofilms offer stability, antimicrobial protection, and facilitate genetic transfer.
Sujet(s)
Antibactériens , Biofilms , Poulets , Multirésistance bactérienne aux médicaments , Enterobacteriaceae , Fermes , Fèces , Tests de sensibilité microbienne , bêta-Lactamases , Animaux , Biofilms/croissance et développement , Biofilms/effets des médicaments et des substances chimiques , Brésil , bêta-Lactamases/génétique , bêta-Lactamases/métabolisme , Fèces/microbiologie , Enterobacteriaceae/effets des médicaments et des substances chimiques , Enterobacteriaceae/isolement et purification , Enterobacteriaceae/génétique , Antibactériens/pharmacologie , Poulets/microbiologie , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme , Volaille/microbiologie , Infections à Enterobacteriaceae/microbiologie , Infections à Enterobacteriaceae/médecine vétérinaireRÉSUMÉ
Raoultella planticola is a Gram-negative, aerobic, nonmotile bacterium that is ubiquitous in the environment usually implicated in opportunistic infections. There have been very few reported cases of Raoultella planticola infection in the pediatric population. Most of these reports have been in cases of neonatal septicemia. This case report describes a case of a 3-day-old Hispanic full-term male that presented with recalcitrant hyperbilirubinemia despite maximal phototherapy found to have urinary tract infection with Raoultella planticola on multiple cultures. The patient's hyperbilirubinemia appropriately responded to treatment of the UTI. This report highlights that, albeit rare, neonatal UTI can present as recalcitrant hyperbilirubinemia. Raoultella planticola is a rare organism that is normally found in the environment but may be a bona fide etiologic agent in neonatal UTI.
Sujet(s)
Infections à Enterobacteriaceae , Infections urinaires , Humains , Infections urinaires/diagnostic , Infections urinaires/microbiologie , Infections urinaires/traitement médicamenteux , Infections urinaires/complications , Mâle , Nouveau-né , Infections à Enterobacteriaceae/diagnostic , Infections à Enterobacteriaceae/traitement médicamenteux , Infections à Enterobacteriaceae/microbiologie , Enterobacteriaceae/isolement et purification , Hyperbilirubinémie , Antibactériens/usage thérapeutiqueRÉSUMÉ
BACKGROUND: Infections due to Citrobacter species are increasingly observed in hospitalized patients and are often multidrug-resistant. Yet, the magnitude and burden of Citrobacter spp. resistance in the hospital setting have not been reported. We aimed to evaluate the epidemiology of Citrobacter spp. infections among hospitalized patients, their main resistance patterns and Citrobacter spp. involvement in hospital outbreaks. METHODS: We conducted a systematic review and meta-analysis of published literature (PROSPERO registration Jan-2023, CRD42023390084). We searched Embase, Medline and grey literature for studies on hospitalized patients diagnosed with Citrobacter spp. infections, and nosocomial outbreaks due to Citrobacter spp. published during the years 2000-2022. We included observational, interventional, surveillance studies and outbreak reports. Outcomes of interest were the frequency of Citrobacter spp. infections among hospitalized patients and 3rd generation cephalosporin and/or carbapenem resistance percentages in these infections. We used random-effects models to generate pooled outcome estimates and evaluated risk of bias and quality of reporting of outbreaks. RESULTS: We screened 1609 deduplicated publications, assessed 148 full-texts, and included 41 studies (15 observational, 13 surveillance and 13 outbreak studies). Citrobacter spp. urinary tract- and bloodstream infections were most frequently reported, with Citrobacter freundii being the main causative species. Hospital-acquired infection occurred in 85% (838/990) of hospitalized patients with Citrobacter infection. After 2010, an increasing number of patients with Citrobacter spp. infections was reported in observational studies. Pooled frequency estimates for Citrobacter spp. infections could not be generated due to lack of data. The pooled prevalence of ESBL and carbapenemase producers among Citrobacter isolates were 22% (95%CI 4-50%, 7 studies) and 18% (95%CI 0-63%, 4 studies), respectively. An increased frequency of reported Citrobacter outbreaks was observed after 2016, with an infection/colonization ratio of 1:3 and a case-fatality ratio of 7% (6/89 patients). Common outbreak sources were sinks, toilets, contaminated food and injection material. Implemented preventive measures included environmental cleaning, isolation of positive patients and reinforcement of hand hygiene. Only seven out of 13 outbreaks (54%) were definitively controlled. CONCLUSION: This review highlights the clinical importance of endemic and epidemic Citrobacter spp. in healthcare settings. As an emerging, multidrugresistant nosocomial pathogen it requires heightened awareness and further dedicated surveillance efforts.
Sujet(s)
Citrobacter , Infection croisée , Infections à Enterobacteriaceae , Humains , Infections à Enterobacteriaceae/épidémiologie , Infections à Enterobacteriaceae/microbiologie , Citrobacter/isolement et purification , Infection croisée/épidémiologie , Infection croisée/microbiologie , Hospitalisation/statistiques et données numériques , Antibactériens/pharmacologie , Antibactériens/usage thérapeutique , Épidémies de maladies , Multirésistance bactérienne aux médicaments , Infections urinaires/épidémiologie , Infections urinaires/microbiologieRÉSUMÉ
BACKGROUND: Carbapenemase-producing Enterobacterales (CPE) are challenging in healthcare, with resistance to multiple classes of antibiotics. This study describes the emergence of imipenemase (IMP)-encoding CPE among diverse Enterobacterales species between 2016 and 2019 across a London regional network. METHODS: We performed a network analysis of patient pathways, using electronic health records, to identify contacts between IMP-encoding CPE-positive patients. Genomes of IMP-encoding CPE isolates were overlaid with patient contacts to imply potential transmission events. RESULTS: Genomic analysis of 84 Enterobacterales isolates revealed diverse species (predominantly Klebsiella spp, Enterobacter spp, and Escherichia coli); 86% (72 of 84) harbored an IncHI2 plasmid carrying blaIMP and colistin resistance gene mcr-9 (68 of 72). Phylogenetic analysis of IncHI2 plasmids identified 3 lineages showing significant association with patient contacts and movements between 4 hospital sites and across medical specialties, which was missed in initial investigations. CONCLUSIONS: Combined, our patient network and plasmid analyses demonstrate an interspecies, plasmid-mediated outbreak of blaIMPCPE, which remained unidentified during standard investigations. With DNA sequencing and multimodal data incorporation, the outbreak investigation approach proposed here provides a framework for real-time identification of key factors causing pathogen spread. Plasmid-level outbreak analysis reveals that resistance spread may be wider than suspected, allowing more interventions to stop transmission within hospital networks.SummaryThis was an investigation, using integrated pathway networks and genomics methods, of the emergence of imipenemase-encoding carbapenemase-producing Enterobacterales among diverse Enterobacterales species between 2016 and 2019 in patients across a London regional hospital network, which was missed on routine investigations.
Sujet(s)
Protéines bactériennes , Épidémies de maladies , Infections à Enterobacteriaceae , Plasmides , bêta-Lactamases , Humains , Plasmides/génétique , bêta-Lactamases/génétique , Infections à Enterobacteriaceae/épidémiologie , Infections à Enterobacteriaceae/microbiologie , Infections à Enterobacteriaceae/transmission , Protéines bactériennes/génétique , Londres/épidémiologie , Antibactériens/pharmacologie , Phylogenèse , Génome bactérien , Mâle , Femelle , Adulte d'âge moyen , Tests de sensibilité microbienne , Adulte , Enterobacteriaceae/génétique , Enterobacteriaceae/effets des médicaments et des substances chimiques , Sujet âgé , Enterobacteriaceae résistantes aux carbapénèmes/génétique , Enterobacteriaceae résistantes aux carbapénèmes/isolement et purification , Colistine/pharmacologieRÉSUMÉ
INTRODUCTION: Carbapenem-resistant Enterobacterales (CRE) causing severe infections in humans have represented an important challenge for clinicians worldwide during the past two decades. AREAS COVERED: Novel ß-lactams and ß-lactam/ß-lactamase inhibitor combinations have led to a shift in the first-line approach to the treatment of severe CRE infections from polymyxin-based regimens to treatment with less toxic agents. This new scenario offers the opportunity to apply rapid molecular diagnostic tests for CRE infection to identify different types of carbapenemases. Herein, the authors provide an overview of this subject and follow it with their expert perspectives. EXPERT OPINION: When considering studies actually measuring the clinical impact of rapid molecular tests in real-life scenarios, high certainty evidence from randomized controlled trials is still limited and not focused on CRE infections. Nonetheless, it is indisputable that rapid molecular tests have been shown to impact early therapeutic choices (in terms of both escalation and de-escalation) when used in real-life settings, thus issues in the clinical interpretation of their results are already relevant. Overall, increased expertise is required for the appropriate interpretation of rapid molecular tests for personalized antibiotic selection by understanding their strengths and limitations.
Sujet(s)
Antibactériens , Enterobacteriaceae résistantes aux carbapénèmes , Infections à Enterobacteriaceae , Techniques de diagnostic moléculaire , Humains , Techniques de diagnostic moléculaire/méthodes , Infections à Enterobacteriaceae/diagnostic , Infections à Enterobacteriaceae/traitement médicamenteux , Infections à Enterobacteriaceae/microbiologie , Enterobacteriaceae résistantes aux carbapénèmes/effets des médicaments et des substances chimiques , Enterobacteriaceae résistantes aux carbapénèmes/génétique , Antibactériens/usage thérapeutique , Antibactériens/pharmacologie , bêta-Lactamases/métabolisme , bêta-Lactamases/génétique , Carbapénèmes/usage thérapeutique , Carbapénèmes/pharmacologie , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme , Tests de sensibilité microbienne/méthodesRÉSUMÉ
The VITEK®2 AES ß-lactam phenotypes of 488 Enterobacterales from North and Latin America generated by the VITEK®2 were compared to the resistance genotypes provided by whole genome sequencing (WGS). The AES provided phenotypic reports for 447 (91.6 %) isolates, including isolates harbouring carbapenemases (195; 43.6 %), ESBLs (103; 23.0 %) and transferable AmpCs (tAmpC; 28; 6.3 %) genes, as well as wildtype isolates (WT; 121; 27.1 %). Overall, the AES report was accurate for 433/447 (96.9 %) isolates. The AES accurately reported carbapenemase, ESBL, and tAmpC phenotypes for 93.7 %, 93.7 %, and 98.4 % of isolates, respectively, and sensitivity/specificity rates were 96.4 %/91.7 %, 98.1 %/92.4 %, 82.1 %/99.5 %, and 100 %/98.8 %. 14 isolates carrying carbapenemase (7 total; 3 KPC, 2 MBL, 2 OXA-48-like), ESBL (2), and tAmpC-encoding genes (5) were not correctly identified by AES. The AES phenotypic report detected resistance mechanisms among Enterobacterales rapidly and could significantly aid future antimicrobial stewardship initiatives and patient care.
Sujet(s)
Protéines bactériennes , Infections à Enterobacteriaceae , Enterobacteriaceae , Tests de sensibilité microbienne , Phénotype , Séquençage du génome entier , bêta-Lactamases , Amérique latine , Humains , Enterobacteriaceae/génétique , Enterobacteriaceae/effets des médicaments et des substances chimiques , bêta-Lactamases/génétique , Infections à Enterobacteriaceae/microbiologie , Protéines bactériennes/génétique , Résistance aux bêta-lactamines/génétique , Antibactériens/pharmacologie , Amérique du Nord , bêta-Lactames/pharmacologie , Génotype , Génome bactérien/génétiqueRÉSUMÉ
BACKGROUND: Carbapenem Resistant Enterobacterales (CRE) infections are increasingly associated with or directly responsible for morbidity and mortality from bacterial infections in sub-Saharan Africa where there are limited antibiotic options. CRE rectal colonization of patients in healthcare facilities provides a reservoir of these organisms and could potentially cause invasive infections in these settings. The prevalence of rectal carriage among patients attending healthcare facilities in Nigeria has not been previously described. We set out to assess the prevalence of rectal CRE carriage and their antibiotic susceptibility patterns among patients attending healthcare facilities in Nigeria. METHODS: A descriptive cross-sectional study was carried out from December 2021 to September 2022 in Ibadan, in which patients attending primary, secondary and tertiary healthcare facilities were screened for rectal carriage of CRE by microscopy, culture and sensitivity of rectal swab specimens. RESULTS: A total of 291 patients were screened; 45 (15.5%), 66 (22.7%) and 180 (61.8%) at primary, secondary and tertiary healthcare facilities, respectively. All but one of them had received a third-generation cephalosporin or carbapenem in the preceding 30 days. The mean age was 28.8 years and 55.7% were male. Overall, 51 (17.5%) participants had CRE colonization, with 5(11.1%), 9(13.6%) and 37(20.6%) at primary, secondary and tertiary healthcare facilities, respectively (p = 0.243). Regarding antimicrobial susceptibility, 43(84.3%) CRE isolates were resistant to at least 3 different classes of antibiotics while two Escherichia coli isolates were resistant to all 5 classes of antibiotics tested. The lowest rates of CRE resistance were to tigecycline (6, 11.5%) and colistin (8, 15.7%). CONCLUSIONS: In this first study on CRE colonization in Nigeria, we found that a substantial proportion of patients in three levels of healthcare facilities had rectal carriage of CRE, including pan-resistant isolates. Active surveillance and appropriate infection prevention and control practices (IPC) need to be urgently strengthened to mitigate the risk of active CRE infection. TRIAL REGISTRATION: Not applicable.